Status:
UNKNOWN
A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML
Lead Sponsor:
Xuejie Jiang
Conditions:
Leukemia, Myeloid
Eligibility:
All Genders
14-60 years
Phase:
PHASE2
Brief Summary
It is often impossible to find therapeutic target in intermediate-risk AML, so it is very important to select appropriate chemotherapy protocol to eliminate minimal residual disease (MRD) in these AML...
Eligibility Criteria
Inclusion
- AML patients with normal heart, lung, liver and renal function, or without serious infection. ECOG score is below 2
Exclusion
- AML patients with abnormal heart, lung, liver and renal function, or with serious infection. ECOG score is over 2
Key Trial Info
Start Date :
February 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 31 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03417427
Start Date
February 1 2018
End Date
January 31 2025
Last Update
April 27 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nanfang Hospital of Southern Medical University
Guanzhou, Guangdong, China, 510515